Success Metrics

Active Trials

1(20%)

Phase Distribution

Ph early_phase_1

80%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

4(80.0%)

Phase 1Safety & dosage

1(20.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(2)

Detailed Status

unknown2

Not yet recruiting2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 14 (80.0%)

Phase 11 (20.0%)

Trials by Status

unknown240%

not_yet_recruiting240%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

recruitingearly_phase_1

Safety and Efficacy of NK510 to Treat NSCLC

NCT06097962

not_yet_recruitingphase_1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

NCT07307053

not_yet_recruitingearly_phase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT06097962Early Phase 1

Safety and Efficacy of NK510 to Treat NSCLC

Recruiting

NCT07307053Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not Yet Recruiting

NCT07166263Early Phase 1

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Not Yet Recruiting

NCT06117878Early Phase 1

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Unknown

NCT06098898Early Phase 1

Safety and Efficacy of NK510 to Treat Gastric Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5